Table 4.
Period (days) from commencing systemic glucocorticoid treatment to developing a side effect for dogs under primary veterinary care in the UK (n = 148).
| Active substance | No. dogs (%) | Median (days) | IQR | Range (days) |
|---|---|---|---|---|
| Oral tablets without preceding injection | ||||
| Prednisolone 1 mg | 4 (2.7) | 11 | 5.0–15.5 | 3.0–16 |
| Prednisolone 5mg | 65 (43.9) | 13 | 7.0–18.0 | 1.0–30 |
| Prednisolone 25mg | 16 (10.8) | 10.5 | 6.5–19.0 | 4.0–25 |
| Methylprednisolone | 4 (2.7) | 4.5 | 1.0–13.5 | 0–20 |
| Prednisolone/cinchophen | 1 (0.7) | 5 | ||
| Overall tablets without preceding injection | 90 (60.8) | 12.5 | 7.0–18.0 | 0–30 |
| Tablets with preceding injection | ||||
| Prednisolone 5 mg | 12 (8.1) | 9 | 6.0–9.5 | 3.0–20 |
| Prednisolone 25 mg | 2 (1.4) | 1.5 | 0–3.0 | 0–3.0 |
| Overall tablets with preceding injection | 14 (9.5) | 8 | 3.0–9.0 | 0–20 |
| Injectable only | ||||
| Dexamethasone Isonicotinate | 3 (2.0) | 7 | 6.0–21 | 6.0–21 |
| Dexamethasone phenylpropionate, dexamethasone sodium phosphate | 11 (7.4) | 17 | 11–24 | 2.0–28 |
| Dexamethasone sodium phosphate | 29 (19.6) | 7 | 4.0–14 | 1.0–31 |
| Methylprednisolone Acetate | 1 (0.7) | 6 | ||
| Overall injectables | 44 (29.7) | 8 | 5.5–20 | 1.0–31 |
| Total | 148 |